Does ciprofloxacin have a lower risk of tendon rupture compared with levofloxacin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ciprofloxacin and Levofloxacin Have Similar Tendon Rupture Risk

Based on the available evidence, ciprofloxacin does NOT have a consistently lower risk of tendon rupture compared to levofloxacin—the data are mixed and conflicting. While some studies suggest levofloxacin may carry higher risk, others show no difference, and both drugs carry FDA black box warnings for this serious adverse event 1, 2.

Evidence Summary

FDA Drug Labels: Class-Wide Warning

Both ciprofloxacin and levofloxacin carry identical FDA black box warnings for tendinopathy and tendon rupture 1, 2. The FDA considers this a class-wide effect affecting all fluoroquinolones, with risk factors including:

  • Age >60 years
  • Concomitant corticosteroid use
  • Kidney, heart, or lung transplant recipients
  • Strenuous physical activity
  • Renal failure
  • Previous tendon disorders (rheumatoid arthritis)

Conflicting Research Evidence

Studies suggesting levofloxacin has HIGHER risk:

  • A 2020 retrospective study of 1 million Medicare beneficiaries found levofloxacin showed 16% increased risk for all tendon ruptures (HR=1.16) and 120% increased risk for Achilles tendon rupture (HR=2.20), while ciprofloxacin showed NO increased risk (HR=0.96) 3

  • A 2015 FDA adverse event analysis found levofloxacin had the highest signal detection score (EBGM=55.2) compared to ciprofloxacin (EBGM=20.0), with 1,555 reports for levofloxacin versus 606 for ciprofloxacin 4

  • A 2016 clinical review concluded levofloxacin and its parent compound ofloxacin possess higher propensities to cause tendon damage relative to other fluoroquinolones, with risk being exposure-dependent 5

Studies showing NO difference or opposite findings:

  • A 2019 meta-analysis found fluoroquinolones as a class increased tendon injury risk, but when analyzing specific agents for Achilles tendon rupture, neither ciprofloxacin nor levofloxacin showed statistically significant increased risk, while ofloxacin and norfloxacin did 6

  • A 2024 meta-analysis found identical expected risk rates of 0.17% for both levofloxacin and ciprofloxacin, while ofloxacin showed significantly higher risk at 1.40% 7

  • A 2003 case-control study found adjusted odds ratios of 3.6 for ciprofloxacin and 28.4 for ofloxacin in patients ≥60 years, suggesting ciprofloxacin may actually be safer 8

Clinical Guidelines Perspective

The 2011 PM&R guidelines emphasize that tendon rupture is a class-wide effect of all fluoroquinolones, with an estimated rate of 15-20 per 100,000 treated adult patients 9. The guidelines note that while multiple fluoroquinolones have been implicated, the evidence does not consistently distinguish risk between individual agents 9.

Clinical Recommendation

Do not assume ciprofloxacin is safer than levofloxacin for tendon rupture risk. Both agents carry substantial risk, particularly in:

  • Patients >60 years: Risk increases 4-fold 9
  • Concomitant corticosteroid users: Risk increases to OR 43.2 for Achilles rupture when combined with fluoroquinolones 9
  • Transplant recipients, renal failure patients, athletes

Practical Approach:

  1. Avoid both agents when possible in high-risk patients (elderly, corticosteroid users, athletes, transplant recipients)

  2. If fluoroquinolone necessary: Choose based on antimicrobial spectrum and indication, NOT on perceived tendon safety differences between ciprofloxacin and levofloxacin

  3. Counsel ALL patients receiving either drug about tendon pain as an early warning sign requiring immediate discontinuation 1, 2

  4. Consider ofloxacin the highest risk fluoroquinolone based on most consistent evidence 6, 8, 7

  5. Monitor for symptoms occurring as early as 2 hours or as late as 6 months post-treatment 9

Important Caveat:

The conflicting evidence likely reflects confounding by indication bias—sicker patients may receive levofloxacin more frequently for respiratory infections, artificially inflating its apparent risk 3. The safest approach is to treat both agents as having equivalent tendon rupture risk and make prescribing decisions based on other clinical factors.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.